Similar articles for PMID: 10971270

Year	Number of Results
1989	1
1992	1
1993	1
1996	2
1997	3
1998	3
1999	1
2000	5
2001	7
2002	11
2003	4
2004	5
2005	4
2006	7
2007	6
2008	4
2009	4
2010	5
2011	7
2012	6
2013	3
2014	2
2015	2
2016	1
2017	5
2018	5
2019	1
2024	0

1

Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer.

Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K. Hatano T, et al. BJU Int. 2000 Sep;86(4):449-52. doi: 10.1046/j.1464-410x.2000.00774.x. BJU Int. 2000. PMID: 10971270

2

[Bone fracture receiving LH-RH agonists for prostatic cancer].

Hatano T, Igarashi H, Nakada J, Oishi Y, Yanada S, Furuta A, Takizawa A, Iwamuro S, Tashiro K. Hatano T, et al. Nihon Hinyokika Gakkai Zasshi. 2000 Jun;91(6):542-6. doi: 10.5980/jpnjurol1989.91.542. Nihon Hinyokika Gakkai Zasshi. 2000. PMID: 10897579 Free article. Japanese.

3

[A clinical study of decreased bone density in the patients treated with long-term luteinizing hormone releasing hormone analogue (LHRH-a)--the risk of iatrogenic osteoporosis due to treatment of carcinoma of prostate].

Suzuki Y, Aikawa K, Oishi Y, Yamazaki H, Onishi T, Suzuki M, Kobari T, Endo K, Yanada S, Kato N, Yoshino Y, Wada T, Ueda M, Takasaka S, Akazawa K. Suzuki Y, et al. Nihon Hinyokika Gakkai Zasshi. 1998 Dec;89(12):961-6. doi: 10.5980/jpnjurol1989.89.961. Nihon Hinyokika Gakkai Zasshi. 1998. PMID: 9990228 Free article. Japanese.

4

Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma.

Townsend MF, Sanders WH, Northway RO, Graham SD Jr. Townsend MF, et al. Cancer. 1997 Feb 1;79(3):545-50. doi: 10.1002/(sici)1097-0142(19970201)79:3<545::aid-cncr17>3.0.co;2-3. Cancer. 1997. PMID: 9028366

5

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.

Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS. Smith MR, et al. N Engl J Med. 2001 Sep 27;345(13):948-55. doi: 10.1056/NEJMoa010845. N Engl J Med. 2001. PMID: 11575286 Free article. Clinical Trial.

6

Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer.

Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Smith MR, et al. J Urol. 2006 Jan;175(1):136-9; discussion 139. doi: 10.1016/S0022-5347(05)00033-9. J Urol. 2006. PMID: 16406890

7

Bone health management in prostate cancer patients receiving androgen deprivation therapy.

Dhanapal V, Reeves DJ. Dhanapal V, et al. J Oncol Pharm Pract. 2012 Mar;18(1):84-90. doi: 10.1177/1078155211402105. Epub 2011 Aug 1. J Oncol Pharm Pract. 2012. PMID: 21807761

8

Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.

Hall MC, Fritzsch RJ, Sagalowsky AI, Ahrens A, Petty B, Roehrborn CG. Hall MC, et al. Urology. 1999 May;53(5):898-902; discussion 902-3. doi: 10.1016/s0090-4295(99)00061-8. Urology. 1999. PMID: 10223480 Clinical Trial.

9

The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.

Diamond T, Campbell J, Bryant C, Lynch W. Diamond T, et al. Cancer. 1998 Oct 15;83(8):1561-6. Cancer. 1998. PMID: 9781950

10

Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer.

Miyaji Y, Saika T, Yamamoto Y, Kusaka N, Arata R, Ebara S, Nasu Y, Tsushima T, Kumon H. Miyaji Y, et al. Urology. 2004 Jul;64(1):128-31. doi: 10.1016/j.urology.2004.03.012. Urology. 2004. PMID: 15245949

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

97 results

Results by year